Redefining Phase 1 for Cancer Trial: The FDA’s Latest Guidance

Early-phase oncology trials operated under a simple, brutal logic: push the dose until the patient breaks, then step back one notch. While that “maximum tolerated dose” mindset made sense for traditional cytotoxic chemotherapy, modern targeted therapies, biologics, and cell therapies play by entirely different biological rules. At the same time, overly rigid eligibility checklists routinely … Read more

How Artificial Intelligence is Quietly Reshaping Clinical Trials 

The integration of artificial intelligence (AI) within clinical research is expanding across multiple medical specialties. While discussions surrounding technological applications in healthcare are frequent, empirical data on how these tools are deployed remains critical. A recent cross-sectional study published in JAMA examines interventional trials to characterize planned artificial intelligence implementations. The study provides a view … Read more

Quality Risk Management in Practice: Operationalizing FDA’s CGT Potency Guidance 

The landscape of cellular and gene therapy (CGT) manufacturing has shifted from isolated lot-release testing toward quality risk management. With the issuance of the FDA’s final guidance, Potency Assurance for Cellular and Gene Therapy Products, regulators have updated the 2011 release-testing framework to emphasize a lifecycle strategy. For regulatory affairs and CMC professionals, this document … Read more

Combination Products: Strategic Implementation of FDA’s EDDC Guidance 

Navigating the evolving landscape of combination product oversight requires regulatory strategy to be as dynamic as the technology itself. With the release of the updated FDA draft guidance on Essential Drug Delivery Device Performance Characteristics (EDDCs), regulatory professionals are presented with a refined framework designed to harmonize drug delivery performance with the Quality Management System … Read more

FDA’s Expands the eSTAR to IDE Submissions 

The last decade, the FDA has been moving the medical device regulatory submissions to a standardized electronic template, the eSTAR. This electronic template replaces guesswork and streamlines regulatory submissions. With the latest expansion of the eSTAR template, now the Investigational Device Exemption (IDE) applications also can be created using the eSTAR template.  The latest FDA … Read more

The Era of N-of-1 Therapeutics: FDA Approval of Individualized Gene Editing Products 

The rapid evolution of genome editing technologies has brought us to the threshold of true precision medicine. For patients suffering from monogenic diseases caused by diverse, patient-specific gene variants, standard gene therapies often fall short. Recognizing this gap, the FDA released a new guidance to suggest how sponsors can bundle multiple product variants under a … Read more

Companion Software: Strategic Insights into the FDA’s Guidance on Prescription Drug Use-Related Software 

Digital health technologies are rapidly transforming prescription therapies from traditional chemical compounds into integrated software-and-drug health systems. As mobile applications and connected devices increasingly accompany pharmaceuticals, life science companies face a complex regulatory matrix. To clarify these boundaries, the FDA issued a new guidance outlining how drug labeling authorities apply to Prescription Drug Use-Related Software … Read more

Building Better Pragmatic Clinical Studies 

Embedded pragmatic clinical trials (ePCTs) test interventions in routine healthcare settings using existing infrastructure, such as electronic health records (EHRs) and frontline clinicians. Unlike traditional trials with strict eligibility criteria and controlled conditions, ePCTs enroll broader, more representative populations to assess whether interventions work in everyday clinical practice. The FDA supports this approach through initiatives … Read more

Mastering Medical Device Safety: Takeaways from the Final Biocompatibility Town Hall 

Navigating medical device biocompatibility evaluations can often feel like solving a maze blindfolded, especially when trying to reconcile shifting global standards with FDA expectations. Fortunately, the FDA recently hosted the final installment of its comprehensive three-part town hall series, bringing together regulatory experts to demystify toxicological risk assessments (TRAs). Drawing from updated consensus standards like … Read more

Fit-for-Purpose Evidence: Why the FDA’s New Rare Disease Framework Matters to Sponsors 

For decades, bringing a rare disease therapy through the regulatory gauntlet has felt less like a science and more like navigating an obstacle course blindfolded. With roughly ninety-five percent of recognized rare conditions still lacking an approved treatment, the human and economic tolls have continued to mount unabated. Traditional clinical trial paradigms simply break down … Read more